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Abstract
Prostacyclins are vasodilatory agents used in the treatment of pulmonary arterial hypertension. The direct effects of prostacyclins
on right heart function are still not clarified. The aim of this study was to investigate the possible direct inotropic properties of
clinical available prostacyclin mimetics in the normal and the pressure-overloaded human right atrium. Trabeculae from the right
atrium were collected during surgery from chronic thromboembolic pulmonary hypertension (CTEPH) patients with pressure-
overloaded right hearts, undergoing pulmonary thromboendarterectomy (n¼ 10) and from patients with normal right hearts
operated by valve replacement or coronary bypass surgery (n¼ 9). The trabeculae were placed in an organ bath, continuously
paced at 1Hz. They were subjected to increasing concentrations of iloprost, treprostinil, epoprostenol, or MRE-269, followed by
isoprenaline to elicit a reference inotropic response. The force of contraction was measured continuously. The expression of
prostanoid receptors was explored through quantitative polymerase chain reaction (qPCR).
Iloprost, treprostinil, epoprostenol, or MRE-269 did not alter force of contraction in any of the trabeculae. Isoprenaline showed
a direct inotropic response in both trabeculae from the pressure-overloaded right atrium and from the normal right atrium.
Control experiments on ventricular trabeculae from the pig failed to show an inotropic response to the prostacyclin mimetics.
qPCR demonstrated varying expression of the different prostanoid receptors in the human atrium. In conclusion, prostacyclin
mimetics did not increase the force of contraction of human atrial trabeculae from the normal or the pressure-overloaded right
heart. These data suggest that prostacyclin mimetics have no direct inotropic effects in the human right atrium.
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Introduction
Right heart failure is the terminal event of several diseases
causing sustained pressure-overload of the right ventricle
(RV), including pulmonary arterial hypertension (PAH),
chronic thromboembolic pulmonary hypertension
(CTEPH), and various congenital heart diseases.1–3
Despite extensive research in the ﬁeld,4–8 there is still a
lack of safe and eﬀective targeted therapies for the right
heart. Characterization of currently used pharmacologic
agents with a potential beneﬁcial eﬀect on the right ventricle
and development of new treatments for the right heart are
required.2
Prostacyclins decrease pulmonary vascular resistance and
afterload for the RV in patients suﬀering from PAH.9 This
eﬀect is mediated through diﬀerent G-protein coupled pros-
tanoid receptors linked to second messenger pathways,
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subsequently resulting in pulmonary vasodilation.10 The
prostacyclins have shown to improve cardiac output in
humans11–13 as well as RV function in several animal
models.14–16 Whether prostacyclins have direct inotropic
eﬀects on the right heart, or if the beneﬁcial eﬀects result
exclusively from decreased pulmonary vascular resistance
and RV afterload reduction, has been debated for decades.
Recent animal studies point towards a direct eﬀect on the
heart of some of the available prostacyclin mimetics.14–17
However, experimental studies in rats and the human left
ventricle suggest that heart failure might attenuate potential
positive eﬀects on the heart.17,18 It is not known if this prob-
lem also applies to the human right heart.
In the current study, we aimed to examine the direct eﬀect
of four diﬀerent, clinically available prostacyclin mimetics
on the force of contraction of the human right atrium from
patients with and without pressure-overload of the right
heart. We also investigated the expression of the prostanoid
receptors in the human right atrium.
Methods
The study was carried out in accordance with the
Declaration of Helsinki and informed consent was obtained
from all the participants involved.19 The protocol was
approved by The National Committee on Health Research
Ethics in Denmark before initiation of the study. The sub-
study involving tissue from pigs conforms to the Principles
of Laboratory Animal Care formulated by the National
Society for Medical Research and the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health.20
Human right atrial trabeculae
The experiments were performed on electrically paced, right
atrial trabeculae as previously described.21,22 Samples of the
right atrial auricle were collected from patients undergoing
elective heart surgery. Two groups of patients were included
in the study by informed consent. CTEPH patients, with
pressure-overloaded right hearts, undergoing pulmonary
thromboendarterectomy (PTEA) (n¼ 10), and patients
undergoing valve replacement or coronary artery bypass
surgery with normal right hearts, serving as healthy controls
(n¼ 9). Patients with atrial ﬁbrillation or ejection fraction
<30 were excluded. Patient characteristics are shown in
Table 1.
In relation to insertion of cardiopulmonary bypass
tubes, a small specimen of the appendage of the right
atrium (5 5mm) was removed. This tissue sample from
the right atrial appendage was collected and immediately
submerged in room temperature Krebs-Henseleit buﬀer
(pH 7.35–7.45). While submerged in the buﬀer, up to
four trabeculae from the right atrial appendage were iso-
lated, placed in an organ bath in 36C oxygenated, mod-
iﬁed Krebs-Henseleit buﬀer ([mmol/L] NaCl2 [112.1], KCl
[4.8], NaHCO3 [42.5], MgCl2 [1.2], KH2PO4 [1.0] CaCl2
[2.0], glucose [10], pyruvic acid [10]), bubbled with 95%
O2 and 5% CO2. The trabeculae were paced continuously
at 1Hz between two electrodes. The rest of the right atrial
tissue was frozen in liquid nitrogen and stored at 80C
for later tissue analysis.
The isolated trabeculae were initially stretched to a pre-
tension of 0.5 g and allowed to stabilize for 75min. After the
stabilization period, each trabeculae was subjected to
increasing concentrations of iloprost (control n¼ 8,
CTEPH n¼ 6), treprostinil (control n¼ 7, CTEPH n¼ 7),
epoprostenol (control n¼ 7, CTEPH n¼ 7), or MRE-269
(control n¼ 7, CTEPH n¼ 5). Each drug was administered
in the buﬀer as six cumulative doses letting the trabeculae
stabilize to each dose for 10min before the next was admin-
istered. At the end of the protocol, one dose of isoprenaline
(30 ug/mL) was administered to induce a reference inotropic
response. Force of contraction was measured continuously
with a force transducer and obtained and analyzed using
Notocord Hem Software (Notocord Systems, France).
Trabeculae that did not reach the threshold of 0.5 g in devel-
oped force after stabilization or with no reaction to isopren-
aline were excluded from the study.
Right atrium versus right ventricle
To determine a potential diﬀerential eﬀect of the prostacyc-
lin mimetics between the right atrium (RA) and the right
ventricle (RV), we obtained right atrial and right ventricular
tissue from eight Danish landrace/Yorkshire pigs
(46 15 kg). With the pig fully anesthetized, a median ster-
notomy was performed. The right atrial appendage and the
RV were cut out of the beating heart and immediately
Table 1. Baseline characteristics of patients.
Control CTEPH
Age, years (mean SD) 67 7 59 19
Male gender, n (%) 5 (56) 5 (50)
BMI, kg/m2 29 4 27 5
Disease duration, months (mean SE) 11.8 4.2 31.8 10
NYHA class III-IV, n (%) 3 (33) 7 (78)
MAP, mmHg (mean SD) 78 35 92 9
PVR, Wood units (mean SD) NA 10.2 4.6
PAP mean, mmHg (mean SD) 19 7 49 8*
CO, L/min (mean SD) 4.4 0.8 4.7 1.8
CI, L/min/m2 (mean SD) NA 2.3 0.6
RAP mean, mmHg (mean SD) NA 9 6
6MWD, m (mean SD) NA 287 137
*P< 0.0001 compared to controls.
6MWD, 6-minute walking distance; BMI, body mass index; CI, cardiac index;
CO, cardiac output; CTEPH, chronic thromboembolic pulmonary hypertension;
EF, ejection fraction; MAP, mean arterial pressure; PAP, pulmonary arterial pres-
sure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SD, stand-
ard deviation; SE, standard error of mean.
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submerged in room temperature Krebs-Henseleit buﬀer.
Trabeculae from the RA and the RV were isolated, mounted
between the pacing electrodes in an organ bath and sub-
jected to increasing concentrations of iloprost (RA n¼ 7,
RV n¼ 7) or treprostinil (RA n¼ 5, RV n¼ 6) as described
in the protocol above.
Expression of prostanoid receptor in the
human right atrium
The frozen human RA tissue was ground in a mortar and
homogenized with TRIzol (Invitrogen, Life Technologies,
UK). The aqueous phase containing the RNA was sepa-
rated from the organic phase with chloroform and precipi-
tated with isopropanolol. The RNA pellet was resuspended
in DEPC water (Invitrogen, Life Technologies, UK). The
quality and concentration of the total RNA were deter-
mined using spectrophotometry (NanoDrop-1000
Spectrophotometer, Thermo Scientiﬁc, USA).
Complementary DNA (cDNA) was synthesized using
Taqman Reverse Transcription Reagents kit (Applied
Biosystems Roche, New Jersey, USA). Real-time polymer-
ase chain reaction (RT-PCR) was carried out using primers
from Qiagen Company, UK (Table 1) in ABI Prism 7900HT
Sequence Detection System (Applied Biosystems, UK).
Gene transcription was measured by Taqman RT-PCR.
The Ct value was calculated as the mean of triplicate meas-
urements. Expression of the prostanoid receptors were cal-
culated as: Expression(gene of interest)¼ 2(Ct reference gene – Ct gene
of interest). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as reference gene.
Materials
Iloprost (Ilomedin) was from Bayer Schering Pharma, tre-
prostinil (Remodulin) was from NordicInfu Care AB,
Sweden, and epoprostenol (Flolan) was from
GlaxoSmithKline, UK, all dissolved in saline and MRE-
269 from Cayman Chemical, USA, dissolved in DMSO
(Merck, Germany). Iloprost was administered in concentra-
tions in the range of 0.02–6 ng/mL, treprostinil in the range
of 0.5–150 ng/mL, epoprostenol in the range of 0.06–20 ng/
mL, and MRE-269 in the range of 30–10,000 ng/mL (Fig. 1).
We aimed to evaluate a broad range of concentrations
including clinical relevant doses. Drug concentrations were
chosen on the basis of previous studies from our labora-
tory,14,17 as well as other studies suggesting inotropic
eﬀect of the prostacyclin mimetics.15,23–26
Statistics
Unpaired t-test and Mann–Whitney test were used to test
diﬀerence in baseline characteristics between controls and
CTEPH patients. The eﬀect of prostacyclin mimetics was
tested using repeated measurements one-way analysis of
variance (ANOVA) or Friedman test followed by a post
hoc multiple comparisons test. Diﬀerence between the
eﬀect on atrial and ventricular tissue was tested with a
two-way ANOVA. A P value< 0.05 was considered statis-
tically signiﬁcant. Data were analyzed using GraphPad
Prism 6.0 (La Jolla, CA, USA) and is presented as
mean standard deviation unless otherwise speciﬁed.
Results
Baseline characteristics
Characteristics of the test participants are presented in
Table 1. Age, gender distribution, and body mass index
did not diﬀer between participants with and without
CTEPH. CTEPH patients presented with elevated pulmon-
ary arterial pressure compared to control patients as well as
Fig. 1. Study design. The right atrial tissue was collected in Krebs-Henseleit buffer, the trabeculae isolated and mounted in the organ bath
between two electrodes pacing at 1Hz. Excess atrial tissue was frozen in liquid nitrogen for later tissue analysis. After 75min of stabilization each
trabecula was subjected to six increasing concentrations of iloprost, treprostinil, epoprostenol, or MRE-269, followed by one dose of isopren-
aline. The drugs were added in cumulative doses to the buffer surrounding the trabecula.
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high pulmonary vascular resistance and low 6-minute walk-
ing distance (Table 1). None of the patients received treat-
ment with prostacyclin mimetics at the time of the
experiment.
Effect of prostacyclin mimetics on human right
atrial trabeculae
Baseline force of contraction was higher in trabeculae from
controls compared to CTEPH patients (Fig. 2a). However,
there was no diﬀerence in maximum force of contraction
(isoprenaline force – baseline force) between the two
groups (Fig. 2b). Neither iloprost, treprostinil, epoproste-
nol, nor MRE-269 increased force of contraction in any of
the trabeculae. MRE-269 had a non-signiﬁcant negative
eﬀect in trabeculae from both control patients (P¼ 0.06)
and CTEPH patients (P¼ 0.09) (Fig. 3). There were no dif-
ferences between the eﬀect on controls and CTEPH of any
of the agents (p(interaction)¼ non-signiﬁcant).
We found no diﬀerence in maximum response to isopren-
aline between trabeculae from controls and trabeculae from
CTEPH patients (Control vs. CTEPH force sd:
0.52 0.40 g vs. 0.65 0.41 g, P¼ 0.17).
Right atrium versus right ventricle
Baseline force of contraction was lower in trabeculae from
the right atrium than trabeculae from the right ventricle
(force sd: RA 0.5 0.39 g vs. RV 1.2 0.94 g, P¼ 0.034)
obtained from pigs.
Iloprost increased force of contraction in the right atrium
(P¼ 0.001) whereas it had no eﬀect on the right ventricle
(RA vs. RV p(interaction)¼ 0.015, two-way ANOVA)
(Fig. 4a).
Treprostinil had no eﬀect on either the right atrium or the
right ventricle (Fig. 4b). Isoprenaline increased force of con-
traction in both atrial and ventricular trabeculae, conﬁrming
a contractile potential.
Expression of prostanoid receptors in the human
right atrium
In the right atrium from both controls and CTEPH patients,
the EP4 receptor was abundantly expressed. The IP, EP2, and
DP receptors were less abundantly expressed whereas there
was a very low expression of the EP1, EP3, FP, and TP recep-
tors. In the right atrium from CTEPH patients, expression of
EP2 was reduced compared to controls (messenger RNA
[mRNA] expression mean diﬀerence control vs. CTEPH:
0.0011, 95% CI, 0.00017–0.0019; P¼ 0.02) (Fig. 5).
Discussion
In the present study, we investigated the eﬀects of four clin-
ically available prostacyclin mimetics on force of contrac-
tion of the human right atrium. Using heart tissue from
patients with normal right hearts as well as CTEPH
patients, we were able to examine whether there was a
potential diﬀerential eﬀect on the normal and the pres-
sure-overloaded right heart. We observed no changes in
force of contraction in the human atrium when the prosta-
cyclin mimetics were administered. A contractile reserve was
consistently observed with administration of isoprenaline.
Patients were chosen to represent two distinct groups,
one with pressure-overloaded right hearts and one with
normal right hearts. The CTEPH patients included in this
study all presented with markedly elevated pulmonary vas-
cular resistance, pulmonary artery pressures, and severely
reduced functional level similar to previous studies of
patients with this condition.27,28 This was not the case for
the control group and they were considered to have a
normal right heart.
We found that none of the four prostacyclin mimetics
had a direct eﬀect on force of contraction in the human
right atrium. This contradicts our previous studies where
we found iloprost, treprostinil, and MRE-269 to improve
right heart function in the healthy rat.14,17 In these studies
Fig. 2. (a) Baseline force of contraction and (b) Maximum force of contraction.
CTEPH, chronic thromboembolic pulmonary hypertension; NS, non-significant.
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Fig. 3. Effect of (a) iloprost, (b) treprostinil, (c) epoprostenol, and (d) MRE-269 on human right atrial trabeculae. Data are presented as mean
force of contraction relative to baseline (100%)þ standard deviation.
Fig. 4. Effect of (a) iloprost and (b) treprostinil on right atrial and right ventricular trabeculae from the pig. Data are presented as mean force of
contraction relative to baseline (100%)þ standard deviation. *P< 0.05, **P< 0.01, Dunn’s multiple comparisons test.
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we used ﬁxed afterload and the isolated heart model to
avoid measuring non-cardiac eﬀects of the prostacyclin
mimetics rather than a direct eﬀect on the heart. However,
changes in RV function resulting from eﬀects in the systemic
and coronary circulation cannot be ruled out. In the present
study, we used isolated muscle trabeculae in organ baths,
where the prostacyclin mimetics are delivered to the cardi-
omyocytes through diﬀusion. This allowed us to investigate
the direct eﬀect on the atrial myocardial tissue separated
from systemic eﬀects and changes in coronary ﬂow.
Riise et al. found iloprost to have a transient negative
inotropy in the non-failing human left ventricle and a sus-
tained negative inotropy in the failing left ventricle.18 We
did not observe negative inotropic eﬀects of the prostacyclin
mimetics, yet a tendency towards reduced force of contrac-
tion was found when MRE-269 was administered in the
highest concentrations. Riise et al. suggest the negative ino-
tropic eﬀect to be mediated by the IP receptor and our
ﬁndings may support this, as MRE-269 is considered a
selective IP receptor agonist, though this agent can act inde-
pendently of the IP receptor in the rat.29
As the right and the left heart are embryologically diﬀer-
ently derived, results from the left heart cannot
automatically be extrapolated to the right heart.30 This con-
curs with the study from Ueno et al., demonstrating a posi-
tive inotropic eﬀect in the left myocardium of the
prostacyclin analogue, beraprost, but no eﬀect on the right
myocardium from the guinea pig.31 Our study suggests that
eﬀects of prostacyclin mimetics on the right heart are not
due to direct actions on the cardiomyocytes, which is sup-
ported by a number of other studies from the RV proposing
the eﬀect to be primarily a consequence of vasodilatation in
the pulmonary and/or coronary circulation and not a direct
eﬀect on the RV.17,32,33
Pharmacological eﬀects on atrial trabeculae may not
completely reﬂect eﬀects on the ventricular myocardium.21
Using right atrial tissue, we were concerned that we might
miss that the right ventricle could be more sensitive to the
prostacyclin mimetics. For obvious reasons, the diﬀerent
response to prostacyclin mimetics between ventricular and
atrial tissue can only be investigated in an animal model. To
explore whether the RV responds better to the prostacyclin
mimetics than the RA, we conducted a separate set of
experiments, comparing the eﬀects of iloprost and trepros-
tinil on right atrial trabeculae to right ventricular trabeculae
from the pig. Neither iloprost nor treprostinil altered the
Fig. 5. Expression of mRNA for the prostanoid receptor subtypes in the right atrium, quantified by PCR. The data were normalized to the
reference gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Control n¼ 9, CTEPH n¼ 7. Results are presented as mean SEM.
*P< 0.05, **P< 0.01, ***P< 0.001, student’s t-test.
CTEPH, chronic thromboembolic pulmonary hypertension; mRNA, messenger RNA.
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force of contraction in the ventricular trabeculae, though
iloprost actually had a positive eﬀect in the atrial trabeculae.
These results suggest that the pig and human atrium do not
respond in a similar fashion to prostacyclin mimetics.
Therefore, we cannot expect that the human and porcine
ventricle would respond similarly to prostacyclin mimetics.
Our results, however, do not support that prostacyclin
mimetics improve porcine ventricular contractility and it
could be speculated that these ﬁndings translate to humans.
Increasing evidence suggests the prostacyclin mimetics
not only work through the IP receptor, but through multiple
prostanoid receptors with varying aﬃnity and selectivity
(Table 2).10,34,35 A lack of prostanoid receptors in the
right atrial myocardium could not be the reason for the
missing response to the prostanoid mimetics in our study,
as all prostanoid receptors were expressed in the right
atrium. However, EP1, EP3, FP, and TP were only found
in very low concentrations compared to the other receptors.
This agrees with previous ﬁndings showing selective FP and
TP receptor agonists unable to change the contractility of
the human myocardium.18 The EP4 receptor was the most
abundantly expressed of the prostanoid receptors agreeing
with previous ﬁndings.36 This may explain signiﬁcant con-
tractile eﬀects in pig atria with iloprost, as this agent has
been reported to activate this receptor in the lung,37 albeit
probably outside the normal clinical dose-range of the drug.
Other prostacyclin mimetics used in this study have a rela-
tively low aﬃnity for the EP4 receptor and thus will prob-
ably not activate the EP4 receptor.
10 We observed a reduced
expression of EP2 receptors in the pressure-overloaded right
atrium compared to the normal right atrium, whereas
expression of this receptor is maintained in the pulmonary
vasculature in a monocrotaline model of PAH associated
with heart failure.37 Whether this depressed expression in
the current model has any functional consequences is, how-
ever, not clear from this study. Treprostinil has high aﬃnity
for the EP2 receptor with at Ki of 3.6 nM
34 corresponding to
the second concentration used in this study, which is
towards the lower end of concentrations obtained clinic-
ally.38 We did not see any eﬀect of this or any higher con-
centration of treprostinil, thus the EP2 receptor is unlikely to
have important direct eﬀects on the cardiomyocytes in the
right atrium. Iloprost and treprostinil both have low aﬃnity
for the EP4 receptor with Ki of 212 nM and 826 nM respect-
ively.34 Concentrations necessary to occupy and activate the
EP4 receptor are way above clinical relevant concentrations
and not tested in the present study.
Limitations
This study was carried out on isolated human trabeculae.
Direct eﬀects on the heart are only a part of the many eﬀects
of prostacyclin mimetics in the intact organism, adding up
to the net eﬀect on the whole cardiovascular system. Yet, the
aim of this study was to investigate the isolated, direct eﬀect
on the human right myocardium, which, to our knowledge,
this study is the ﬁrst to do.
We did not normalize trabecular force to preparation
size. As we use a constant preload of 0.5 g, diﬀerent prep-
arations sizes may have diﬀerent strains, which could intro-
duce a potential bias.
Experiments comparing the eﬀects on the right atrium
versus the right ventricle were carried out in trabeculae
from the pig. Animal experiments may not be directly trans-
ferable to humans, however, considering the obvious chal-
lenges in obtaining tissue from the live human ventricle, we
chose to use the pig, a well-accepted animal model in car-
diovascular research.
Conclusion
In conclusion, this study demonstrates that prostacyclin
mimetics have no direct inotropic eﬀects on cardiomyocytes
in the human right atrium, though prostanoid receptors,
which the prostacyclin mimetics are likely to activate, were
expressed.
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